Targeting of liposomes to lymph nodes

Liposome Technology: Interactions of Liposomes with the Biological Milieu

Volumn , Issue , 2006, Pages 231-252

  Phillips, William T ^a   Goins, Beth A ^a   Medina, Luis A ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956914777     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (58)

1. Hirnle P. Liposomes for drug targeting in the lymphatic system. Hybridoma 1997; 16(1):127-132.
2. Phillips WT, Klipper R, Goins B. Novel method of greatly enhanced delivery of liposomes to lymph nodes. J Pharmacol Exp Ther 2000; 295(1):309-313.
3. Oussoren C, Storm G. Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev 2001; 50(1-2):143-156.
4. Duzgunes N, Simoes S, Slepushkin V, et al. Enhanced inhibition of HIV-1 replication in macrophages by antisense oligonucleotides, ribozymes and acyclic nucleoside phosphonate analogs delivered in pH-sensitive liposomes. Nucleosides Nucleotides Nucleic Acids 2001; 20(4-7):515-523.
5. Swartz MA. The physiology of the lymphatic system. Adv Drug Deliv Rev 2001; 50(1-2):3-20.
6. Swartz MA, Skobe M. Lymphatic function, lymphangiogenesis, and cancer metastasis. Microsc Res Tech 2001; 55(2):92-99.
7. Hawley A, Davis S, Illum L. Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics. Adv Drug Delivery Rev 1995; 17:129-148.
8. Porter CJ. Drug delivery to the lymphatic system. Crit Rev Ther Drug Carrier Syst 1997; 14(4):333-393.
9. Porter CJ, Charman WN. Transport and absorption of drugs via the lymphatic system. Adv Drug Deliv Rev 2001; 50(1-2):1-2.
10. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1):57-70.
11. Torabi M, Aquino SL, Harisinghani MG. Current concepts in lymph node imaging. J Nucl Med 2004; 45(9):1509-1518.
12. Busby JE, Evans CP. Old friends, new ways: revisiting extended lymphadenectomy and neoadjuvant chemotherapy to improve outcomes. Curr Opin Urol 2004; 14(5):251-257.
13. Gagne JF, Desormeaux A, Perron S, et al. Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. Biochim Biophys Acta 2002; 1558(2):198-210.
14. Cohen OJ, Pantaleo G, Lam GK, et al. Studies on lymphoid tissue from HIVinfected individuals: implications for the design of therapeutic strategies. Springer Semin Immunopathol 1997; 18(3):305-322.
15. Desormeaux A, Bergeron MG. Lymphoid tissue targeting of anti-HIV drugs using liposomes. Methods Enzymol 2005; 391:330-351.
16. El Setouhy M, Ramzy RM, Ahmed ES, et al. A randomized clinical trial comparing single- and multi-dose combination therapy with diethylcarbamazine and albendazole for treatment of bancroftian filariasis. Am J Trop Med Hyg 2004; 70(2):191-196.
17. Dixon TC, Meselson M, Guillemin J, et al. Anthrax. N Engl J Med 1999; 341(11):815-826.
18. Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001; 7(6):933-944.
19. Barakat LA, Quentzel HL, Jernigan JA, et al. Fatal inhalational anthrax in a 94-year-old Connecticut woman. JAMA 2002; 287(7):863-868.
20. Ilgazli A, Boyaci H, Basyiglt I, et al. Extrapulmonary tuberculosis: clinical and epidemiologic spectrum of 636 cases. Arch Med Res 2004; 35(5):435-441.
21. Bermudez LE. Use of liposome preparation to treat mycobacterial infections. Immunobiology 1994; 191(4-5):578-583.
22. Zinkernagel RM, Ehl S, Aichele P, et al. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 1997; 156:199-209.
23. Schijns VE. Induction and direction of immune responses by vaccine adjuvants. Crit Rev Immunol 2001; 21(1-3):75-85.
24. Johansen P, Haffner AC, Koch F, et al. Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur J Immunol 2005; 35(2):568-574.
25. Gregoriadis G, Bacon A, Caparros-Wanderley W, et al. A role for liposomes in genetic vaccination. Vaccine 2002; 20(suppl 5):B1-B9.
26. Maloy KJ, Erdmann I, Basch V, et al. Intralymphatic immunization enhances DNA vaccination. Proc Natl Acad Sci USA 2001; 98(6):3299-3303.
27. Osborne MP, Richardson VJ, Jeyasingh K, et al. Radionuclide-labelled liposomes- a new lymph node imaging agent. Int J Nucl Med Biol 1979; 6(2):75-83.
28. Patel HM, Boodle KM, Vaughan-Jones R. Assessment of the potential uses of liposomes for lymphoscintigraphy and lymphatic drug deliver. Failure of 99m-technetium marker to represent intact liposomes in lymph nodes. Biochim Biophys Acta 1984; 801(1):76-86.
29. Love WG, Amos N, Williams BD, et al. Effect of liposome surface charge on the stability of technetium (99mTc) radiolabelled liposomes. J Microencapsul 1989; 6(1):105-113.
30. AndersenAR, FribergH, LassenNA, et al.Serial studies of cerebral blood flowusing 99Tcm-HMPAO: a comparison with 133Xe. Nucl Med Comm 1987; 8(7):549-557.
31. Phillips WT, Rudolph AS, Goins B, et al. A simple method for producing a technetium-99m-labeled liposome which is stable in vivo. Int J Rad Appl Instrum B 1992; 19(5):539-547.
32. Goins BA, Phillips WT. Radiolabelled liposomes for imaging and biodistribution studies. In: Torchilin VP, Weissig V, eds. Liposomes: A Practical Approach. Oxford: Oxford University Press, 2003:319-336.
33. Phillips WT, Andrews T, Liu H, et al. Evaluation of [(99m)Tc] liposomes as lymphoscintigraphic agents: comparison with [(99m)Tc] sulfur colloid and [(99m)Tc] human serum albumin. Nucl Med Biol 2001; 28(4):435-444.
34. Phillips WT, Klipper R, Goins B. Use of (99m)Tc-labeled liposomes encapsulating blue dye for identification of the sentinel lymph node. J Nucl Med 2001; 42(3):446-451.
35. Harrington KJ, Rowlinson-Busza G, Syrigos KN, et al. Pegylated liposomes have potential as vehicles for intratumoral and subcutaneous drug delivery. Clin Cancer Res 2000; 6(6):2528-2537.
36. Oussoren C, Zuidema J, Crommelin DJ, et al. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose. Biochim Biophys Acta 1997; 1328(2):261-272.
37. Oussoren C, Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. III. Influence of surface modification with poly(ethylene glycol). Pharm Res 1997; 14(10):1479-1484.
38. Oussoren C, Velinova M, Scherphof G, et al. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. IV. Fate of liposomes in regional lymph nodes. Biochim Biophys Acta 1998; 1370(2):259-272.
39. Mangat S, Patel HM. Lymph node localization of non-specific antibody-coated liposomes. Life Sci 1985; 36(20):1917-1925.
40. Wu MS, Robbins JC, Bugianesi RL, et al. Modified in vivo behavior of liposomes containing synthetic glycolipids. Biochim Biophys Acta 1981; 674(1):19-29.
41. Trubetskoy VS, Whiteman KR, Torchilin VP, et al. Massage-induced release of subcutaneously injected liposome-encapsulated drugs to the blood. J Control Release 1998; 50(1-3):13-19.
42. Velinova M, Read N, Kirby C, et al. Morphological observations on the fate of liposomes in the regional lymph nodes after footpad injection into rats. Biochim Biophys Acta 1996; 1299(2):207-215.
43. Van Rooijen N, Kors N, vd Ende M, et al. Depletion and repopulation of macrophages in spleen and liver of rat after intravenous treatment with liposome- encapsulated dichloromethylene diphosphonate. Cell Tissue Res 1990; 260(2):215-222.
44. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages:mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994; 174(1-2):83-93.
45. Oussoren C, Storm G. Role of macrophages in the localisation of liposomes in lymph nodes after subcutaneous administration. Int J Pharm 1999; 183(1):37-41.
46. Fielding RM, Moon-McDermott L, Lewis RO. Bioavailability of a small unilamellar low-clearance liposomal amikacin formulation after extravascular administration. J Drug Target 1999; 6(6):415-426.
47. Duzgunes N, Perumal VK, Kesavalu L, et al. Enhanced effect of liposomeencapsulated amikacin on Mycobacterium avium-M. intracellulare complex infection in beige mice. Antimicrob Agents Chemother 1988; 32(9):1404-1411.
48. Dufresne I, Desormeaux A, Bestman-Smith J, et al. Targeting lymph nodes with liposomes bearing anti-HLA-DR Fab0 fragments. Biochim Biophys Acta 1999; 1421(2):284-294.
49. Segal AW, Gregoriadis G, Black CD. Liposomes as vehicles for the local release of drugs. Clin Sci Mol Med 1975; 49(2):99-106.
50. Hirnle P, Harzmann R, Wright JK. Patent blue V encapsulation in liposomes:potential applicability to endolympatic therapy and preoperative chromolymphography. Lymphology 1988; 21(3):187-189.
51. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127(4):392-399.
52. Focht SL. Lymphatic mapping and sentinel lymph node biopsy. AORN J 1999; 69(4):802-809.
53. Pump B, Hirnle P. Preoperative lymph-node staining with liposomes containing patent blue violet. A clinical case report. J Pharm Pharmacol 1996; 48(7):699-701.
54. Dieter M, Schubert R, Hirnle P. Blue liposomes for identification of the sentinel lymph nodes in pigs. Lymphology 2003; 36(1):39-47.
55. Plut EM, Hinkle GH, Guo W, et al. Kit formulation for the preparation of radioactive blue liposomes for sentinel node lymphoscintigraphy. J Pharm Sci 2002; 91(7):1717-1732.
56. Medina LA, Calixto SM, Klipper R, et al. Avidin/biotin-liposome system injected in the pleural space for drug delivery to mediastinal lymph nodes. J Pharm Sci 2004; 93(10):2595-2608.
57. Medina LA, Klipper R, Phillips WT, et al. Pharmacokinetics and biodistribution of [111In]-avidin and [99mTc]-biotin-liposomes injected in the pleural space for the targeting of mediastinal nodes. Nucl Med Biol 2004; 31(1):41-51.
58. Bao A, Goins B, Klipper R, et al. 186Re-liposome labeling using 186Re-SNS/S complexes: in vitro stability, imaging, and biodistribution in rats. J Nucl Med 2003; 44(12):1992-1999.